En

ua ru

Ursis®

Drugs from the National List of Medicines Prescription drugs
Film-coated tablets
Dosage:
250 mg №50 500 mg №50
Category:
Biliary pathology treatment. ATC Code A05A A02., Medicines used for liver diseases, lipotropic substances. ATX code A05B.
Active ingredient:
ursodeoxycholic acid

Download the manual

Indications for use

Dissolution of X-ray-negative cholesterol gallstones no more than 15 mm in diameter in patients with a functioning gallbladder, despite the presence of gallstone(s). Symptomatic treatment of primary biliary cirrhosis (PBC) in the absence of decompensated liver cirrhosis. Treatment of hepatobiliary disorders in cystic fibrosis in children aged 6 to 18 years.

Знайти в аптеках: Compendium Tabletki.ua LIKI24

Information about medications intended exclusively for doctors and pharmacists.

INSTRUCTIONS

for medical use of the medicinal product

 

URSIS®

(URSIS)

Composition:

active substance: ursodeoxycholic acid;

1 tablet contains ursodeoxycholic acid 500 mg;

excipients: microcrystalline cellulose, crospovidone, povidone, polysorbate 80, talc, colloidal anhydrous silica, magnesium stearate;

coating: Opadry Clear film-coating mixture: hypromellose (hydroxypropyl methylcellulose), talc, polyethylene glycol (macrogol).

 

Pharmaceutical form. Film-coated tablets.

Main physicochemical properties: oblong tablets with a biconvex surface, scored on both sides, film-coated, white or almost white in colour.

 

Pharmacotherapeutic group. Agents used for the treatment of the liver and biliary tract. Agents used in biliary pathology.

ATC code A05A A02.

Agents used in liver disease, lipotropic substances.

ATC code A05B.

 

Pharmacological properties

Pharmacodynamics

A small amount of ursodeoxycholic acid is found in human bile. After oral administration, ursodeoxycholic acid reduces the cholesterol saturation of bile by inhibiting intestinal absorption of cholesterol and decreasing cholesterol secretion into bile. Gradual dissolution of gallstones is probably due to the dispersion of cholesterol and the formation of liquid crystals.

According to current knowledge, the effect of ursodeoxycholic acid in liver diseases and cholestasis is thought to be due to the relative replacement of lipophilic, detergent-like, toxic bile acids by the hydrophilic, cytoprotective, non-toxic ursodeoxycholic acid, to an improvement in the secretory capacity of hepatocytes, and to immunoregulatory processes.

Use in children

Cystic fibrosis

Information is available from clinical reports on the long-term use of ursodeoxycholic acid (for periods of up to 10 years) in the treatment of children with hepatobiliary disorders associated with cystic fibrosis. There is evidence that the use of ursodeoxycholic acid may reduce proliferation in the bile ducts, halt the progression of histological changes and even reverse hepatobiliary changes, provided that therapy is started at an early stage of cystic fibrosis. For better treatment efficacy, therapy with ursodeoxycholic acid should be started immediately after the diagnosis of cystic fibrosis has been established.

Pharmacokinetics

After oral administration, ursodeoxycholic acid is rapidly absorbed in the jejunum and the upper ileum by passive transport, and in the terminal ileum by active transport. The absorption rate is generally 60–80 %. After absorption, the bile acid undergoes almost complete conjugation in the liver with the amino acids glycine and taurine and is then excreted in the bile. The first-pass hepatic clearance is up to 60 %.

Depending on the daily dose and on the underlying disorder or condition of the liver, the more hydrophilic ursodeoxycholic acid accumulates in the bile. At the same time, a relative decrease in other, more lipophilic bile acids is observed.

Under the influence of intestinal bacteria, partial degradation to 7-ketolithocholic and lithocholic acids takes place. Lithocholic acid is hepatotoxic and causes damage to the liver parenchyma in some animal species. In humans, only a very small amount of it is absorbed; it is sulfated in the liver and thus detoxified before being excreted in the bile and, finally, in the faeces.

The biological half-life of ursodeoxycholic acid is 3.5–5.8 days.

 

Clinical particulars

Indications

For the dissolution of radiolucent cholesterol gallstones no more than 15 mm in diameter in patients with a functioning gallbladder, despite the presence of gallstone(s) in it.

For the symptomatic treatment of primary biliary cholangitis (PBC), provided there is no decompensated liver cirrhosis.

For the treatment of hepatobiliary disorders in cystic fibrosis in children aged 6 to 18 years.

 

Contraindications

- Hypersensitivity to any substance contained in the medicinal product.

- Acute inflammation of the gallbladder or bile ducts.

- Obstruction of the bile duct (obstruction of the common bile duct or cystic duct).

- Frequent episodes of hepatic colic.

- Radiopaque calcified gallbladder stones.

- Impaired gallbladder contractility.

- Decompensated liver cirrhosis.

- Unsuccessful portoenterostomy or absence of adequate bile flow in children with biliary atresia.

 

Interaction with other medicinal products and other forms of interaction

The medicinal product Ursis® must not be used concomitantly with cholestyramine, colestipol or antacids containing aluminium hydroxide and/or smectite (aluminium oxide), since these preparations bind ursodeoxycholic acid in the intestine and thus impair its absorption and reduce its efficacy. If the use of preparations containing one of the above-mentioned substances is necessary, they should be taken at least 2 hours before or 2 hours after taking the medicinal product.

The medicinal product Ursis® may increase the absorption of ciclosporin from the intestine. In patients receiving ciclosporin, the physician should check the blood concentration of this substance and, if necessary, adjust the ciclosporin dose.

In isolated cases, the medicinal product may reduce the absorption of ciprofloxacin.

It is known that in a clinical study in healthy volunteers, concomitant administration of ursodeoxycholic acid (500 mg/day) and rosuvastatin (20 mg/day) led to a slight increase in plasma rosuvastatin levels. The clinical relevance of this interaction with other statins is unknown.

Ursodeoxycholic acid reduces the maximum plasma concentration (Cmax) and the area under the concentration-time curve (AUC) of the calcium antagonist nitrendipine.

Close monitoring of the results of concomitant use of nitrendipine and ursodeoxycholic acid is recommended. An increase in the nitrendipine dose may be necessary. In view of this, as well as taking into account the report of one case of interaction with dapsone (reduced therapeutic effect) and in vitro studies, it may be concluded that ursodeoxycholic acid induces the cytochrome P450 3A enzyme, which metabolises medicinal products. However, no induction was observed in a well-designed interaction study with budesonide, which is a known cytochrome P450 3A substrate.

Oestrogenic hormones and blood cholesterol-lowering agents such as clofibrate increase hepatic cholesterol secretion and, consequently, may promote biliary lithiasis, which counteracts ursodeoxycholic acid used for the dissolution of gallstones.

Therefore, when medicinal products metabolised by the P450 3A enzyme are used concomitantly, special caution should be exercised, bearing in mind that dose adjustment may be possible if necessary.

 

Special warnings and precautions for use

The medicinal product Ursis® should be taken under medical supervision.

During the first 3 months of therapy, the physician should monitor liver function parameters – AST (SGOT), ALT (SGPT) and γ-GT – every 4 weeks, and every 3 months thereafter. This makes it possible to determine whether or not patients with PBC are responding to treatment, and to detect potential liver function impairment in a timely manner, especially in patients with late-stage PBC.

Use for the dissolution of cholesterol gallstones

6–10 months after the start of treatment, the general appearance of the stone and the appearance of gallbladder obstruction should be determined by oral cholecystography, with the patient in the standing and supine positions (ultrasound examination). This is necessary to assess therapeutic progress and to detect possible calcification of the gallstones in a timely manner.

The medicinal product must not be taken by patients with a gallbladder that cannot be visualised by X-ray methods, with calcified stones, impaired gallbladder contractility, or frequent biliary colic.

Female patients taking the medicinal product Ursis® for the dissolution of gallstones should use an effective non-hormonal method of contraception, since hormonal contraceptives may promote the formation of gallstones (see the sections “Interaction with other medicinal products and other forms of interaction” and “Use during pregnancy or breast-feeding”).

Treatment of patients with late-stage PBC

Cases of decompensation of liver cirrhosis, which partially regressed after discontinuation of therapy, have been reported extremely rarely.

In patients with PBC, worsening of symptoms may very rarely occur at the start of treatment; for example, pruritus may increase. In such cases, the dose of Ursis®, film-coated tablets, 500 mg should be reduced to half a tablet of Ursis® 500 mg per day; the dose should then be increased gradually, as described in the section “Method of administration and doses”.

If diarrhoea develops, the dose should be reduced; if the diarrhoea becomes persistent, treatment should be discontinued.

 

Use during pregnancy or breast-feeding

Animal studies have shown no effect of ursodeoxycholic acid on fertility. There are no data on the effect on fertility in humans.

There are insufficient data on the use of ursodeoxycholic acid in pregnant women. Animal studies indicate reproductive toxicity in early pregnancy. Ursodeoxycholic acid should not be used in pregnant women unless there is an urgent need. Women of childbearing potential should take the medicinal product only if reliable contraception is used.

The use of non-hormonal contraceptives or low-oestrogen oral contraceptives is recommended. Patients receiving ursodeoxycholic acid for the dissolution of gallstones should use effective non-hormonal methods of contraception, since hormonal oral contraceptives may promote the formation of gallstones. The possibility of pregnancy should be excluded before the start of treatment.

According to several documented cases of use of the medicinal product in breast-feeding women, the content of ursodeoxycholic acid in breast milk was extremely low; therefore, no adverse reactions are expected in breast-fed infants.

 

Ability to affect reaction speed when driving vehicles or operating other machinery

No effect on the ability to drive or operate other machinery has been observed.

 

Method of administration and doses

There are no age restrictions for the use of Ursis® tablets.

Patients with a body weight of less than 47 kg, or those who have difficulty swallowing tablets, may be given ursodeoxycholic acid in another pharmaceutical form.

For the dissolution of cholesterol gallstones

Approximately 10 mg of ursodeoxycholic acid per 1 kilogram of body weight per day (see Table 1)

Table 1

Body weight

Number of tablets

up to 60 kg

61–80 kg

81–100 kg

over 100 kg

1

1 ½

2

2 ½

 

The tablets should be swallowed whole with a small amount of liquid, in the evening before bedtime.

The tablets should be taken regularly.

The time required for the dissolution of gallstones is usually 6–24 months. If no reduction in the size of the gallstones is observed after 12 months of treatment, therapy should not be continued.

The success of treatment should be checked every 6 months by ultrasound or X-ray examination. Additional examinations should be performed to check whether calcification of the stones has occurred over time. If it has, treatment should be discontinued.

For the symptomatic treatment of primary biliary cholangitis (PBC)

The daily dose depends on body weight and varies from 1½ to 3½ tablets (14 ± 2 mg of ursodeoxycholic acid per kilogram of body weight), see Table 2.

During the first 3 months of treatment, the medicinal product should be taken with the daily dose divided into 3 doses throughout the day. When liver function parameters improve, the daily dose may be taken once a day, in the evening.

 

Table 2

Body weight (kg)

Ursis®, film-coated tablets, 500 mg

first 3 months

thereafter

morning

midday

evening

evening

(once a day)

47–62

½

½

½

1 ½

63–78

½

½

1

2

79–93

½

1

1

2 ½

94–109

1

1

1

3

over 110

1

1

1 ½

3 ½

 

The tablets should be swallowed without chewing, with liquid. The medicinal product must be used regularly.

Use of the medicinal product in primary biliary cholangitis is possible for a long period of time.

In patients with primary biliary cholangitis, clinical symptoms may rarely worsen at the start of treatment; for example, pruritus may increase. In this case, therapy should be continued with half a tablet of Ursis® per day, after which the dose should be increased gradually (by increasing the daily dose by half a tablet of Ursis® each week until the indicated dosage regimen is reached).

Use in children

Children with cystic fibrosis aged 6 to 18 years

The dose is 20 mg/kg/day, divided into 2–3 doses, with a subsequent increase in the dose to 30 mg/kg/day if necessary.

 

Table 3

Body weight

(kg)

Daily dose

(mg/kg)

 

Ursis®, film-coated tablets, 500 mg

Morning

Midday

Evening

20–29

17–25

½

--

½

30–39

19–25

½

½

½

40–49

20–25

½

½

1

50–59

21–25

½

1

1

60–69

22–25

1

1

1

70–79

22–25

1

1

1½

80–89

22–25

1

1½

1½

90–99

23–25

1½

1½

1½

100–109

23–25

1½

1½

2

>110

 

1½

2

2

Children

For the dissolution of cholesterol gallstones and the symptomatic treatment of PBC:

there are no fundamental age restrictions for the use of Ursis® in children; however, for children with a body weight of less than 47 kg and/or children who have difficulty swallowing, it is recommended to use ursodeoxycholic acid in the form of a suspension.

For the treatment of hepatobiliary disorders in cystic fibrosis:

use in children aged 6 to 18 years.

 

Overdose

In case of overdose, diarrhoea may occur. Other symptoms of overdose are unlikely, since the absorption of ursodeoxycholic acid decreases with increasing dose, and therefore most of the dose taken is excreted in the faeces.

If diarrhoea occurs, the dose should be reduced, and if the diarrhoea is persistent, therapy should be discontinued.

Treatment is symptomatic and involves restoring the fluid and electrolyte balance.

Additional information on special patient populations

Long-term therapy with high doses of ursodeoxycholic acid (28–30 mg/kg/day) in patients with primary sclerosing cholangitis (off-label use) was associated with a higher incidence of serious adverse events.

 

Adverse reactions

Adverse reactions observed during clinical studies and during the use of the medicinal product Ursis®, film-coated tablets, 500 mg, are listed in the table below by system organ class according to MedDRA [Medical Dictionary for Regulatory Activities] and by frequency.

System organ class

Common

(from ≥ 1/100 to ˂ 1/10)

Very rare

(˂ 1/10,000)

Frequency not known (cannot be estimated from the available data)

Gastrointestinal disorders

Loose stools or diarrhoea

Severe pain in the right upper abdomen during treatment of PBC

Nausea, vomiting

Hepatobiliary disorders

Calcification of gallstones, decompensation of liver cirrhosis1

Skin and subcutaneous tissue disorders

Rash (urticaria)

Pruritus

1 Observed during therapy of late-stage PBC and partially regressed after discontinuation of treatment.

Reporting of suspected adverse reactions

Reporting of adverse reactions after authorisation of a medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and lack of efficacy of the medicinal product via the Automated Pharmacovigilance Information System at: https://aisf.dec.gov.ua.

 

Shelf life. 2 years.

 

Storage conditions

Store in the original package at a temperature not exceeding 25 °C.

Keep out of the reach of children.

 

Package

10 tablets in a blister; 3 blisters in a carton.

10 tablets in a blister; 5 blisters in a carton.

10 tablets in a blister; 10 blisters in a carton.

 

Dispensing category. By prescription.

 

Manufacturer. JSC “KYIV VITAMIN PLANT”.

 

Location of the manufacturer and address of its place of business

38 Kopylivska Street, Kyiv, 04073, Ukraine.

 

Date of last revision. 07.09.2026

 


Information about medications intended exclusively for doctors and pharmacists.

Правова угода про отримання інформації
Цей розділ сайту АТ «КИЇВСЬКИЙ ВІТАМІННИЙ ЗАВОД» призначений виключно для медичних та фармацевтичних працівників та містить професійну спеціалізовану інформацію про лікарські засоби, медичні вироби: їх назву, склад, характеристики, способи застосування, лікувальні властивості, можливу побічну дію, можливі протипоказання, іншу професійну спеціалізовану інформацію.

Інформація про лікарські засоби, медичні вироби виробництва АТ «КИЇВСЬКИЙ ВІТАМІННИЙ ЗАВОД» призначена виключно для ознайомлення і не може слугувати для самостійної діагностики чи лікування, а також для використання з метою надання порад чи рекомендацій.

У випадку, якщо Ви не є медичним або фармацевтичним працівником але обираєте опцію «Так, підтверджую», Ви порушуєте умови даної угоди. У зв'язку з цим АТ «КИЇВСЬКИЙ ВІТАМІННИЙ ЗАВОД» не несе відповідальності за наслідки використання Вами інформації про лікарські засоби та медичні вироби, а також попереджає, що самолікування може бути шкідливим для Вашого здоров'я, а застосуванню лікарських засобів, медичних виробів має передувати консультація лікаря.

Я підтверджую, що є медичним або фармацевтичним працівником, розумію її зміст і підтверджую свою згоду з нею.